AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 132.66 Increased By ▲ 3.13 (2.42%)
BOP 6.89 Increased By ▲ 0.21 (3.14%)
CNERGY 4.57 Decreased By ▼ -0.06 (-1.3%)
DCL 8.92 Decreased By ▼ -0.02 (-0.22%)
DFML 42.75 Increased By ▲ 1.06 (2.54%)
DGKC 84.00 Increased By ▲ 0.23 (0.27%)
FCCL 32.90 Increased By ▲ 0.13 (0.4%)
FFBL 77.06 Increased By ▲ 1.59 (2.11%)
FFL 12.20 Increased By ▲ 0.73 (6.36%)
HUBC 110.01 Decreased By ▼ -0.54 (-0.49%)
HUMNL 14.40 Decreased By ▼ -0.16 (-1.1%)
KEL 5.53 Increased By ▲ 0.14 (2.6%)
KOSM 8.32 Decreased By ▼ -0.08 (-0.95%)
MLCF 39.67 Decreased By ▼ -0.12 (-0.3%)
NBP 65.50 Increased By ▲ 5.21 (8.64%)
OGDC 198.74 Decreased By ▼ -0.92 (-0.46%)
PAEL 26.00 Decreased By ▼ -0.65 (-2.44%)
PIBTL 7.62 Decreased By ▼ -0.04 (-0.52%)
PPL 159.00 Increased By ▲ 1.08 (0.68%)
PRL 26.24 Decreased By ▼ -0.49 (-1.83%)
PTC 18.35 Decreased By ▼ -0.11 (-0.6%)
SEARL 82.24 Decreased By ▼ -0.20 (-0.24%)
TELE 8.12 Decreased By ▼ -0.19 (-2.29%)
TOMCL 34.40 Decreased By ▼ -0.11 (-0.32%)
TPLP 8.98 Decreased By ▼ -0.08 (-0.88%)
TREET 16.88 Decreased By ▼ -0.59 (-3.38%)
TRG 59.49 Decreased By ▼ -1.83 (-2.98%)
UNITY 27.52 Increased By ▲ 0.09 (0.33%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 10,614 Increased By 206.9 (1.99%)
BR30 31,874 Increased By 160.5 (0.51%)
KSE100 98,972 Increased By 1644 (1.69%)
KSE30 30,784 Increased By 591.7 (1.96%)
World

US to authorize Pfizer vaccine for age 12 and up: report

  • The people most eager to get their shots have, for the most part, already rolled up their sleeves and done so.
Published May 4, 2021

WASHINGTON: The United States is expected to authorize the Pfizer-BioNTech Covid-19 vaccine for children age 12 and up by early next week, US media reported Monday.

Pfizer has applied for emergency use authorization for its Covid vaccine for children and teenagers between ages 12 and 15, according to CNN, citing a government official.

"The FDA will have to amend the emergency use authorization for the vaccine, but the process should be straightforward," CNN reported.

The US Food and Drug Administration is expected to grant that approval by early next week. After the FDA decision, the Centers for Disease Control and Prevention advisory committee will meet to recommend how the vaccine should be used.

A spokeswoman for the FDA declined to give details on the approval timeline, telling The Washington Post: "We are working to review this request as quickly and transparently as possible."

The Pfizer vaccine is currently authorized for people 16 and older in the United States.

The US pharmaceutical giant said in late March it had submitted data from a clinical trial of 2,260 12- to 15-year-olds that showed the vaccine was highly effective and well-tolerated.

Further testing on younger children is ongoing.

Moderna is conducting trials of its vaccine in teens, with results expected in the summer, as well as in younger children.

Johnson & Johnson is also planning pediatric trials for its vaccine.

Expanding vaccine authorization to include adolescents could open up the US mass vaccination program to millions more people.

The national vaccination rate peaked around April 11, according to official data, and although 55 percent of US adults now have had one or more doses, there's still a long way to go to achieve population immunity against Covid.

The people most eager to get their shots have, for the most part, already rolled up their sleeves and done so.

But vaccine hesitancy remains a major obstacle: a large percentage of US adults don't plan to get the shot and could potentially refuse to get their children vaccinated.

Among Republican voters, 29 percent say they will never take the vaccine, compared to five percent of Democrats and nine percent of independents, according to a recent survey by the Kaiser Family Foundation.

Comments

Comments are closed.